Side Effects of Truvada, Atripla, Viread, Complera and Stribild
The lawyers at Saiontz & Kirk, P.A. are reviewing potential HIV drug lawsuits against Gilead for failing to adequately warn about the toxic effect of medications that contained tenofovir disoproxil fumarate (TDF), and withholding the development of safer HIV treatments for years to maximize profits.
For individuals who experienced side effects that could have been avoided, Truvada, Atripla, Viread, Complera or Stribild HIV Drug Lawsuits are being reviewed for:
- Chronic Kidney Disease (CKD)
- Acute Kidney Injury
- Kidney Failure
- Dialysis Treatment
- Wrongful Death
BONE DENSITY LOSS:
- Bone Fractures
- Tooth Loss or Dental Problems from Bone Deterioration
All cases are reviewed on a contingency fee basis, which means there are no fees or expenses unless a settlement or recovery is obtained. To find out if you or a loved one may be entitled to financial compensation, call 1-800-522-0102 or request a free case review.
History of TDF Drug Problems
In recent years, Gilead has developed an essential monopoly over certain HIV “cocktail” drugs, with the introduction of a series of medications involving the antiretroviral tenofovir. These treatments are critical for individuals living with HIV or at risk of getting the disease (PrEP).
REVIEW YOUR CASE
In 2001, Viread was introduced as the first HIV treatment featuring tenofovir disoproxil fumarate (TDF), which allowed the compound to be taken through a pill, avoiding the need for injections.
This was followed by the introduction of Truvada in 2004, Atripla in 2006, Complera in 2011 and Stribild in 2012, each involving different combination treatments with TDF. As a result, the drug maker was able to maintain blockbuster sales for their newest medications, and delay competition from generic HIV drugs.
In recent years, Gilead has generated more than $11 billion in annual sales, marketing HIV and PrEP drugs with known toxic side effects on the kidneys and the bones.
According to allegations raised in Gilead HIV drug lawsuits, the drug maker placed its desire for profits before consumer safety by delaying development of a known safer alternative design, known as tenofovir alafenamide (TAF), which is effective at a much lower and less toxic dose.
Gilead did not begin to introduce safer TAF drugs, such as Genvoya, Odefsey and Descovy, until the end of patent protection for TDF drugs approached in 2018.
While this scheme allowed the drug maker to generate billions in profits and avoid generic competition until 2032, thousands of individuals throughout the United States have been left with severe kidney damage and bone problems that may have been avoided.
HIV Drug Class Action Lawsuit Allegations
Saiontz & Kirk, P.A. is pursuing claims for damages as a result of the toxic side effects TDF drugs may have on the kidneys and bones. According to allegations that raised in the HIV treatment lawsuits, Gilead:
- Failed to warn about the risk of TDF toxicity;
- Failed to recommend important monitoring for kidney function and bone mineral density;
- Withheld a safer design for alternative HIV drugs for more than a decade;
- Provided false and misleading information about the TDF drug risks;
- Generated billions in sales by placing profits before the health of consumers
No Fees or Expenses Unless You Receive a HIV Drug Settlement
Saiontz & Kirk, P.A. is a nationally known injury law firm that is focused exclusively on representing individuals, we do not represent corporations or insurance companies.
Over the course of more than 40 years, clients of our law firm have collected more than $1 billion in compensation in cases involving product liability, medical malpractice, automobile accidents and other personal injury lawsuits.
All HIV drug toxicity lawsuits are being handled on a contingency fee basis, which means that there are never any out-of-pocket costs to hire our lawyers and we receive no fees or expenses unless a recovery is obtained.
Protect your family and find out if you or a loved one may be entitled to a HIV drug injury settlement.